|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Webb PM and Jordan SJ: Epidemiology of
epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol.
41:3–14. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Arend RC, Jackson-Fisher A, Jacobs IA,
Chou J and Monk BJ: Ovarian cancer: New strategies and emerging
targets for the treatment of patients with advanced disease. Cancer
Biol Ther. 22:89–105. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Falzone L, Scandurra G, Lombardo V,
Gattuso G, Lavoro A, Distefano AB, Scibilia G and Scollo P: A
multidisciplinary approach remains the best strategy to improve and
strengthen the management of ovarian cancer (Review). Int J Oncol.
59:532021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baldwin LA, Huang B, Miller RW, Tucker T,
Goodrich ST, Podzielinski I, DeSimone CP, Ueland FR, van Nagell JR
and Seamon LG: Ten-year relative survival for epithelial ovarian
cancer. Obstet Gynecol. 120:612–618. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yeung TL, Leung CS, Yip KP, Yeung CLA,
Wong STC and Mok SC: Cellular and molecular processes in ovarian
cancer metastasis. A review in the theme: Cell and molecular
processes in cancer metastasis. Am J Physiol Cell Physiol.
309:C444–C456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Camby I, Le Mercier M, Lefranc F and Kiss
R: Galectin-1: A small protein with major functions. Glycobiology.
16:137R–157R. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Janiszewska M, Primi MC and Izard T: Cell
adhesion in cancer: Beyond the migration of single cells. J Biol
Chem. 295:2495–2505. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang RY, Rabinovich GA and Liu FT:
Galectins: Structure, function and therapeutic potential. Exp Rev
Mol Med. 10:e172008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Perillo NL, Marcus ME and Baum LG:
Galectins: Versatile modulators of cell adhesion, cell
proliferation, and cell death. J Mol Med (Berl). 76:402–412. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ham IH, Lee D and Hur H: Role of
cancer-associated fibroblast in gastric cancer progression and
resistance to treatments. J Oncol. 2019:62707842019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chong Y, Tang D, Gao J, Jiang X, Xu C,
Xiong Q, Huang Y, Wang J, Zhou H, Shi Y and Wang D: Galectin-1
induces invasion and the epithelial-mesenchymal transition in human
gastric cancer cells via non-canonical activation of the hedgehog
signaling pathway. Oncotarget. 7:83611–83626. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hsu YL, Hung JY, Chiang SY, Jian SF, Wu
CY, Lin YS, Tsai YM, Chou SH, Tsai MJ and Kuo PL: Lung
cancer-derived galectin-1 contributes to cancer associated
fibroblast-mediated cancer progression and immune suppression
through TDO2/kynurenine axis. Oncotarget. 7:27584–27598. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang PF, Li KS, Shen YH, Gao PT, Dong ZR,
Cai JB, Zhang C, Huang XY, Tian MX, Hu ZQ, et al: Galectin-1
induces hepatocellular carcinoma EMT and sorafenib resistance by
activating FAK/PI3K/AKT signaling. Cell Death Dis. 7:e22012016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu Y, Liu M, Li Z, Wu XB, Wang Y, Wang Y,
Nie M, Huang F, Ju J, Ma C, et al: LYAR promotes colorectal cancer
cell mobility by activating galectin-1 expression. Oncotarget.
6:32890–32901. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Masoodi M, Shah ZA, Beigh AH, Ahmad SZ,
Mir AW, Yasin B, Rasool R, Masoodi KZ and Bhat GM: Galectin-1 as a
predictive biomarker in ovarian cancer. J Ovarian Res. 14:1232021.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Robinson MD, McCarthy DJ and Smyth GK:
edgeR: A Bioconductor package for differential expression analysis
of digital gene expression data. Bioinformatics. 26:139–140. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hu Z, Artibani M, Alsaadi A, Wietek N,
Morotti M, Shi T, Zhong Z, Gonzalez LS, El-Sahhar S, Carrami EM, et
al: The repertoire of Serous Ovarian cancer non-genetic
heterogeneity revealed by single-cell sequencing of normal
fallopian tube epithelial cells. Cancer Cell. 37:226–242. e2272020.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Perets R, Wyant GA, Muto KW, Bijron JG,
Poole BB, Chin KT, Chen JY, Ohman AW, Stepule CD, Kwak S, et al:
Transformation of the fallopian tube secretory epithelium leads to
high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer
Cell. 24:751–765. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Arcolia V, Journe F, Wattier A, Leteurtre
E, Renaud F, Gabius HJ, Remmelink M, Decaestecker C, Rodriguez A,
Boutry S, et al: Galectin-1 is a diagnostic marker involved in
thyroid cancer progression. Int J Oncol. 51:760–770. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chetry M, Song Y, Pan C, Li R, Zhang J and
Zhu X: Effects of Galectin-1 on biological behavior in cervical
cancer. J Cancer. 11:1584–1595. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
van de Vijver MJ, He YD, Veer LJ, Dai H,
Hart AAM, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton
MJ, et al: A gene-expression signature as a predictor of survival
in breast cancer. New Engl J Med. 347:1999–2009. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lankadasari MB, Aparna JS, Mohammed S,
James S, Aoki K, Binu VS, Nair S and Harikumar KB: Targeting
S1PR1/STAT3 loop abrogates desmoplasia and chemosensitizes
pancreatic cancer to gemcitabine. Theranostics. 8:3824–3840. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Paz H, Joo EJ, Chou CH, Fei F, Mayo KH,
Abdel-Azim H, Ghazarian H, Groffen J and Heisterkamp N: Treatment
of B-cell precursor acute lymphoblastic leukemia with the
Galectin-1 inhibitor PTX008. J Exp Clin Cancer Res. 37:672018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Orozco CA, Martinez-Bosch N, Guerrero PE,
Vinaixa J, Dalotto-Moreno T, Iglesias M, Moreno M, Djurec M,
Poirier F, Gabius HJ, et al: Targeting galectin-1 inhibits
pancreatic cancer progression by modulating tumor-stroma crosstalk.
Proc Natl Acad Sci USA. 115:E3769–E3778. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ricciardelli C, Lokman NA, Ween MP and
Oehler MK: WOMEN IN CANCER THEMATIC REVIEW: Ovarian
cancer-peritoneal cell interactions promote extracellular matrix
processing. Endocr Relat Cancer. 23:T155–T168. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kicman A, Niczyporuk M, Kulesza M, Motyka
J and Lawicki S: Utility of matrix metalloproteinases in the
diagnosis, monitoring and prognosis of ovarian cancer patients.
Cancer Manag Res. 14:3359–3382. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Storti P, Marchica V and Giuliani N: Role
of galectins in multiple myeloma. Int J Mol Sci. 18:27402017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li B, Shen W, Peng H, Li Y, Chen F, Zheng
L, Xu J and Jia L: Fibronectin 1 promotes melanoma proliferation
and metastasis by inhibiting apoptosis and regulating EMT. Onco
Targets Ther. 12:3207–3221. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Park J and Schwarzbauer JE: Mammary
epithelial cell interactions with fibronectin stimulate
epithelial-mesenchymal transition. Oncogene. 33:1649–1657. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu WJ, Wang Q, Zhang W and Li L:
Identification and prognostic value of differentially expressed
proteins of patients with platinum resistance epithelial ovarian
cancer in serum. Zhonghua Fu Chan Ke Za Zhi. 51:515–523. 2016.(In
Chinese). PubMed/NCBI
|
|
33
|
Yoshihara M, Kajiyama H, Yokoi A, Sugiyama
M, Koya Y, Yamakita Y, Liu W, Nakamura K, Moriyama Y, Yasui H, et
al: Ovarian cancer-associated mesothelial cells induce acquired
platinum-resistance in peritoneal metastasis via the FN1/Akt
signaling pathway. Int J Cancer. 146:2268–2280. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yokoi A, Matsumoto T, Oguri Y, Hasegawa Y,
Tochimoto M, Nakagawa M and Saegusa M: Upregulation of fibronectin
following loss of p53 function is a poor prognostic factor in
ovarian carcinoma with a unique immunophenotype. Cell Commun
Signal. 18:1032020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Navab R, Strumpf D, To C, Pasko E, Kim KS,
Park CJ, Hai J, Liu J, Jonkman J, Barczyk M, et al: Integrin α11β1
regulates cancer stromal stiffness and promotes tumorigenicity and
metastasis in non-small cell lung cancer. Oncogene. 35:1899–1908.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ando T, Kage H, Matsumoto Y, Zokumasu K,
Yotsumoto T, Maemura K, Amano Y, Watanabe K, Nakajima J, Nagase T,
et al: Integrin alpha 11 in non-small cell lung cancer is
associated with tumor progression and postoperative recurrence.
Cancer Sci. 111:200–208. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Primac I, Maquoi E, Blacher S, Heljasvaara
R, Van Deun J, Smeland HYH, Canale A, Louis T, Stuhr L, Sounni NE,
et al: Stromal integrin alpha 11 regulates PDGFR beta signaling and
promotes breast cancer progression. J Clin Invest. 129:4509–4528.
2019. View Article : Google Scholar
|
|
38
|
Levental KR, Yu H, Kass L, Lakins JN,
Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, et
al: Matrix crosslinking forces tumor progression by enhancing
integrin signaling. Cell. 139:891–906. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gao YF, Zhu T, Chen J, Liu L and Ouyang R:
Knockdown of collagen-1(III) inhibits glioma cell proliferation and
migration and is regulated by miR128-3p. Oncol Lett. 16:1917–1923.
2018.PubMed/NCBI
|
|
40
|
Shen Y, Li X, Wang D, Zhang L, Li X, Su L,
Fan X and Yang X: COL3A1: Potential prognostic predictor for head
and neck cancer based on immune-microenvironment alternative
splicing. Cancer Med. 12:4882–4894. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yuan L, Shu B, Chen L, Qian K, Wang Y,
Qian G, Zhu Y, Cao X, Xie C, Xiao Y and Wang X: Overexpression of
COL3A1 confers a poor prognosis in human bladder cancer identified
by co-expression analysis. Oncotarget. 8:70508–70520. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pelli A, Vayrynen JP, Klintrup K, Makela
J, Makinen MJ, Tuomisto A and Karttunen TJ: Gremlin1 expression
associates with serrated pathway and favourable prognosis in
colorectal cancer. Histopathology. 69:831–838. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gonzalez-Gonzalez L and Alonso J:
Periostin: A matricellular protein with multiple functions in
cancer development and progression. Front Oncol. 8:2252018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yue H, Li W, Chen R, Wang J, Lu X and Li
J: Stromal POSTN induced by TGF-β1 facilitates the migration and
invasion of ovarian cancer. Gynecol Oncol. 160:530–538. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
van den Brule F, Califice S, Garnier F,
Fernandez PL, Berchuck A and Castronovo V: Galectin-1 accumulation
in the ovary carcinoma peritumoral stroma is induced by ovary
carcinoma cells and affects both cancer cell proliferation and
adhesion to laminin-1 and fibronectin. Lab Invest. 83:377–386.
2003. View Article : Google Scholar : PubMed/NCBI
|
